MIAMI, March 09, 2023 – OPKO Health, Inc. (NASDAQ: OPK) today announced that it will hold an R&D Day event on March 20, 2023 beginning at 4:00 p.m. Eastern time. The two-hour virtual event will provide an opportunity to hear from OPKO executives about the ModeX Therapeutics multispecific technology platforms and applications in oncology and infectious diseases. Management will also review the MDX-2201 technology underlying the recently announced license and collaboration agreement with Merck for a vaccine against Epstein-Barr virus. Presenters will include:
• Phillip Frost, M.D., Chief Executive Officer and Chairman
• Elias Zerhouni, M.D., President and Vice Chairman
• Gary Nabel, M.D., Ph.D., Chief Innovation Officer
• Ronnie Wei, Ph.D., Head of Biologics Discovery and Development, ModeX Therapeutics
• John Mascola, M.D., Chief Scientific Officer, ModeX Therapeutics
• Vijay Chhajlani, Ph.D., Chief Technology Officer, ModeX Therapeutics
There is no need to pre-register for the event. A live and archived webcast will be available on OPKO’s Investor Relations website. Following management’s presentations, a Q&A session will be available via the chat function of the webcast.
About ModeX Therapeutics
ModeX Therapeutics is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency in fighting complex disease. The ModeX pipeline includes candidates against both solid and hematologic tumors, as well as several of the world’s most pressing viral threats. Its founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients. ModeX is an OPKO Health company based in Natick, Massachusetts. For more information, please visit www.modextx.com.
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
LHA Investor Relations
Yvonne Briggs, 310-691-7100
Bruce Voss, 310-691-7100